FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Famotidine Injection
Status: Currently in Shortage
»Date first posted: 05/05/2020
»Therapeutic Categories: Gastroenterology

Expand all

Athenex Pharmaceutical Division, LLC (Athenex) (Reverified 07/16/2021)

Company Contact Information:
855-273-0154

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
20 mg per 2 mL (10 mg per mL), single dose vial, PF, (NDC 70860-751-02 and 41) Available Marketed by Athenex. To order, contact Athenex at 855-273-0154
200 mg per 20 mL(10 mg per mL), multiple dose vial with preservatives, (NDC 70860-751-20 and 41) Available Marketed by Athenex. To order, contact Athenex at 855-273-0154

Baxter Healthcare (Reverified 06/29/2021)

Company Contact Information:
888-229-0001

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Famotidine Injection premix, 20mg/50 mL in GALAXY Plastic Container (NDC 0338-5197-41) Available

Fresenius Kabi USA, LLC (Revised 07/22/2021)

Company Contact Information:
888-386-1300

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
20 mg per 2 mL (10 mg per mL), single dose vial, PF, (NDC 63323-739-12) Available Check wholesalers for inventory Demand increase for the drug
40 mg per 4 mL (10 mg per mL), mutilple dose vial, (NDC 63323-738-09) Backordered. Next release September 2021. Check wholesalers for inventory Demand increase for the drug
200 mg per 20 mL(10 mg per mL), multiple dose vial, (NDC 63323-738-20) Available Check wholesalers for inventory Demand increase for the drug

Hikma Pharmaceuticals USA, Inc. (formerly West-Ward) (Revised 07/06/2021)

Company Contact Information:
800-631-2174

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
10 mg/mL, 2 mL vial (NDC 0641-6022-25) Inventory is currently available. Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released. Demand increase for the drug
10 mg/mL, 4 mL vial (NDC 0641-6023-25) This presentation is temporarily on backorder. Additional lots will be scheduled for manufacturing in the July - August 2021 timeframe. Product will be made available as it is released. Demand increase for the drug
10 mg/mL, 20 mL vial (NDC 0641-6021-10) Inventory is currently available. Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released. Demand increase for the drug

Mylan Institutional, a Viatris company (Reverified 07/20/2021)

Company Contact Information:
800-796-9526

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Famotidine Injection (Solution in Multi Dose Vials : Containing Preservatives) [40 mg / 4 ml] 10PK (NDC 67457-448-43) Available Demand increase for the drug
Famotidine Injection (Solution in Multi Dose Vials : Containing Preservatives) [200 mg / 20 ml] 10PK (NDC 67457-457-20) Available Demand increase for the drug
Famotidine Injection (Solution in Single Dose Vials) [20 mg / 2 ml] 25PK (NDC 67457-433-22) Available Demand increase for the drug

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English